ESC Professional Premium Access

Epidemiological aspects of atrial fibrillation

Event: ESC Congress 2022
Topic: Epidemiology, Prognosis, Outcome
Session type: Moderated ePosters
Date: 27 August 2022
Time: 12:15 - 13:00

Congress Session

6 presentations in this session

Changes in incidences of clinical outcomes in patients with newly diagnosed atrial fibrillation: a nationwide study since 2010.

Speaker: Professor L. Fauchier (Tours, FR)

Micronutrient deficiencies and new-onset atrial fibrillation in a community-based cohort: Data from PREVEND

Speaker: Mr A. Al Mubarak (Groningen, NL)

Bone morphogenetic protein 10 as predictor for adverse outcomes in patients with atrial fibrillation

Speaker: Doctor E. Hennings (Basel, CH)

Impact of the atrial fibrillation better care pathway in clinically complex patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF General Long-Term Registry

Speaker: Doctor G. Romiti (Liverpool, GB)

Prediction of incident atrial fibrillation with GDF-15 and echocardiographic left atrial volumes: data from the Akershus cardiac examination 1950 study

Speaker: Doctor P. Roenningen (Baerum, NO)

Incidence and risk factors for residual adverse events despite anticoagulation in atrial fibrillation: results from phase II/III of the GLORIA-AF registry

Speaker: Doctor W. Ding (Liverpool, GB)

6 speakers from this session

Professor Laurent Fauchier

University Hospital of Tours, Tours (France)
12 presentations
1 follower

Mr Ali Al Mubarak

University Medical Centre Groningen, Groningen (Netherlands (The))
0 follower

Doctor Elisa Juliane Hennings

University Hospital Basel, Basel (Switzerland)
0 follower

Doctor Giulio Francesco Romiti

University of Liverpool, Liverpool (United Kingdom of Great Britain & Northern Ireland)
1 presentation
0 follower

Doctor Peter Selmer Roenningen

Baerum Hospital, Baerum (Norway)
1 follower

Doctor Wern Yew Ding

University of Liverpool, Liverpool (United Kingdom of Great Britain & Northern Ireland)
0 follower

This platform is supported by

logo Novo Nordisk